EMPEROR Reduced Trial Evidences Benefit of Heart Failure Prevention Drug Empagliflozin

EMPEROR Reduced Trial Evidences Benefit of Heart Prevention Drug Empagliflozin

Milton Packer, MD, is a distinguished scholar in cardiovascular science working out of Baylor University Medical Center in Dallas. The chair of the department of clinical sciences at the University of Texas Southwestern Medical School, Dr. Packer, recently gave an interview discussing the EMPEROR Reduced study results, sponsored by Boehringer Ingelheim in collaboration with Eli Lilly sought to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.  Dr. Packer called the outcomes in EMPEROR Reduced “very striking.”

The Drug: Empagliflozin

This drug’s trade name is Jardiance and is used along with diet and exercise to treat type 2 diabetes. It was approved for medical use in the USA and in the EU by 2014. Recently, it was reported that the drug met its endpoint in the EMPEROR Reduced study to test whether it can risk heart failure with reduced ejection fraction in patients with and without diabetes.

The Study

The EMPEROR Reduced study started in March 2017 through Spring 2020.


According to an interview recently published and streamed by A...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee